Navigation Links
EnVivo to Share Results of its EVP-6124 Phase Ib/IIa Trial at The International Conference on Alzheimer's Disease
Date:7/7/2009

WATERTOWN, Mass., July 7 /PRNewswire/ --

    WHAT:           EnVivo Pharmaceuticals to share results from its Ib/IIa
                    trial in Alzheimer's disease patients with its
                    nicotinic alpha-7 agonist EVP-6124.

    WHEN:           Wednesday, July 15, 2009.

    WHERE:          Alzheimer's Association 2009 International Conference
                    on Alzheimer's Disease (ICAD) in Vienna, Austria.

    WHO:            Dana Hilt, MD, senior vice president, clinical
                    development and chief medical officer, EnVivo
                    Pharmaceuticals.

    ADDITIONAL:     EVP-6124 is EnVivo's novel alpha-7 nicotinic
                    acetylcholine receptor agonist currently in development
                    for Alzheimer's disease and cognitive dysfunction
                    associated with schizophrenia.  In this trial, safety
                    and effects on cognition of EVP-6124 were tested in
                    Alzheimer's patients already on long term treatment
                    with acetylcholine esterase inhibitors.

About EnVivo Pharmaceuticals

EnVivo Pharmaceuticals, located in Watertown, Mass., is a biopharmaceutical company dedicated to discovering and developing small molecule therapeutics for disorders of the central nervous system, with a current focus on Alzheimer's disease, Cognitive Disorders and Schizophrenia. The company's lead product is an alpha-7 nicotinic acetylcholine receptor agonist and has been tested in Phase 2a clinical trials for cognition disorders in Alzheimer's disease and Schizophrenia. The company's other programs include an epigenetics program based on Histone Deacetylase inhibition (HDACi) with EVP-0334 as the lead molecule for cognition in Alzheimer's disease which is in Phase 1 studies, and several preclinical programs such as a Gamma Secretase Modulator (for Alzheimer's disease) and a PDE10 inhibitor program (for Schizophrenia). For more information about EnVivo, visit www.envivopharma.com.


'/>"/>
SOURCE EnVivo Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. EnVivo and Mitsubishi Tanabe Enter License Agreement on EVP-6124 in Japan, Korea, Taiwan and Other Asian Countries
2. Startech Environmental Advises Shareholders to Take No Action in Response to Friendly LRL Tender Offer
3. Calling All Aspiring Filmmakers! The In The Know Short Film Competition Announces Call for Entries Women and Couples Encouraged to Enter TODAY, Share Their Fertility Stories and Inspire Others
4. Ronald McDonald House Charities(R) (RMHC(R)) and McDonalds(R) Seek Inspiring Stories Through New Share.Give.Hope. Campaign
5. Shared Race, Social Group Seem to Help People Relate
6. Connectyx Technologies Holdings Groups CEO Gives Shareholders a Summary of Events for First Half of 2009 and Announces Teleconference Call on July 9th to Discuss Future Strategy
7. Sally Field Shares Her Osteoporosis Story on EmpowHer
8. Warner Chilcott to Hold 2009 Annual General Meeting of Shareholders and Special Court-Ordered Meeting of Shareholders
9. AlphaRx Shareholder Update
10. Seroquels First- and Second-Line Patient Share Has Grown Since Last Years Analysis of Prescribing Trends in Bipolar Disorder
11. Arcadia Resources Responds to Share Price Volatility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2017)... ... July 26, 2017 , ... “We are thrilled to ... ability for patients to schedule an appointment online in real time,” said Keith English, ... Month Smiles provider directory will bring more Six Month Smiles patients to their providers.” ...
(Date:7/26/2017)... ... ... Musielak, a partner at the Andrew Cores Family Law Group, a division of ... this year. She will serve the membership in this capacity for a term of one ... organization’s by-laws. , Musielak joined the Andrew Cores Family Law Group ...
(Date:7/25/2017)... ... July 25, 2017 , ... Centurion Service Group ... Regional Account Manager for the Northeast and Florida regions. In this role, Jennifer ... obsolete medical assets. , Jennifer joins Centurion with a wealth of knowledge and ...
(Date:7/25/2017)... ... July 25, 2017 , ... ... in the United States, today announced its partnership with financial technology company, Automated ... The foundation of the solution lies within Hyosung’s superior ATMs, assisted self-service devices ...
(Date:7/24/2017)... COLLEGE PARK (PRWEB) , ... July 24, 2017 , ... ... It is bio-compatible, because it produces the same kind of electrical energy that the ... in the form of moving electrons. This flow of electrons out of the battery ...
Breaking Medicine News(10 mins):
(Date:7/19/2017)... 19, 2017  Mako Medical Laboratories partnered with Secretary ... Family Assistance Fund (MFA) to bring 140 soldiers back ... with their families one last time before being deployed. ... travel and logistics needed for these soldiers. "Mako Medical ... their families. We just wish we could bring them ...
(Date:7/13/2017)... , July 13, 2017  Centurion Medical Products, a leader ... DisImpactor ® fecal impaction removal device for hospice patient care. ... Centurion ... Patient pain management and emotional ... Hospice can help alleviate patient pain while preventing unneeded emergency department ...
(Date:7/11/2017)... Research Corp., also known as ,The Epigenetics Company, announced today the release ... manner using the myDNAge ™ test. Based on Horvath,s Clock, so ... and biostatistics at the David Geffen School of Medicine at UCLA ... DNAge ™ technology is used to analyze DNA methylation patterns of ... ...
Breaking Medicine Technology: